Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Stock Code : BSE –

150 million

er Center in Odisha Listed on BSE and NSE HCG Kolkata to launch 1 st Radixact in India ~ USD 150 million equity Investment from CVC Capital 1 st Digital PET CT in India 4 www . h c g e l . c o m Pio

rs 29

Chennai Double Road S h a r e h o l d i n g P a t t e r n a s o f S e p ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2

13%

Double Road S h a r e h o l d i n g P a t t e r n a s o f S e p ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2) Incl

58%

le Road S h a r e h o l d i n g P a t t e r n a s o f S e p ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2) Includes

1.6x

ies HCG is committed to provide last mile cancer care across India and is the largest player with >1.6x footprint of CCCs as compared to the next largest player MARKET LEADERSHIP ACROSS REGIONS(1) ME

100%

Hospitals and Omega Hospitals; FY22 revenue for all others. Note: Oncology share is assumed to be 100% for Tata Memorial and Omega Hospitals. For Apollo Hospitals, only hospital revenue (Healthcare Serv

RS 9

10 Successfully Decoded Non -metro Business Model MARKET LEADER IN ALMOST ALL NON-METRO CENTERS 9 NON-METRO CENTERS WITH HIGH-TEEN ROCE SUCCESSFUL SCALABLE NON-METRO MODEL Jaipur Baroda Nagpur

15%

12 9 9 Market Leadership (11) Top 3 in other Non-metro Centers (2) All Non- Metro Centers >15% EBITDA Margin >20% EBITDA Margin > 15% ROCE(1) Key Parameters(1) Metro Non-Metro Revenue

20%

dership (11) Top 3 in other Non-metro Centers (2) All Non- Metro Centers >15% EBITDA Margin >20% EBITDA Margin > 15% ROCE(1) Key Parameters(1) Metro Non-Metro Revenue CAGR(2) 18% 17% Av

18%

Margin >20% EBITDA Margin > 15% ROCE(1) Key Parameters(1) Metro Non-Metro Revenue CAGR(2) 18% 17% Average EBITDA % 25% 23% Payor Mix(3) 84% 52% Note: Figures for H1’23; (1) For establis

17%

n >20% EBITDA Margin > 15% ROCE(1) Key Parameters(1) Metro Non-Metro Revenue CAGR(2) 18% 17% Average EBITDA % 25% 23% Payor Mix(3) 84% 52% Note: Figures for H1’23; (1) For established c

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“c o m Successful Playbook of Smart Acquisitions and Driving Sustained Growth Post Integration Time tested and highly replicable model of consistent revenue growth and profitability across geographies Acquisition Year Revenue CAGR(2) Margin Expansion (2) Key Interventions HCG Ahmedabad (Metro City) HCG Cuttack (Non-metro City) 2013(1) c.”

“The management plans to prudently invest to grow these businesses going forward 14 www .”

“BS Ajai Kumar Executive Chairman Visionary and key driving force of HCG, with an aim to make advanced cancer care accessible Raj Gore Whole-time Director and CEO Seasoned healthcare leader with 20+ years in management across North America, Asia & Africa Abhay Prabhakar Havaldar Non-Executive Independent Director Established General Atlantic’s India Office.”

“No Particulars Capex incurred till 30 th Sep 2022 Expected Capex between Oct 22 to Mar 23 Expected Capex for FY24 Total Planned Capex Expected date of Operations 1 2 Ahmedabad – Phase II Whitefield (Extension of Bangalore - COE) 70.0 10.0 146.2 40.0 635.8 200.0 852.0 250.0 Q1 FY25 Q4 FY24 1.”

Subject

1

Subject

Stock Code : BSE – 539787, NSE – HCG Investor Presentation We wish to inform you that the Board of Directors of the Company, at their meeting held on November 10, 2022, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022. In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2022. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P RESENTATI ON November 2022 SAFE HARBOR This presentation and its contents are confidential and are not for release,